MedTrace Logo

Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure

NCT04498780 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2026-04-08

No results posted yet for this study

Summary

Sacubitril-Valsartan reduced heart failure hospitalizations and cardiovascular mortality compared to enelapril in chronic heart failure. Furthermore, quality of life is improved. The decrease of NT-proBNP levels during Sacubitril-Valsartan treatment is associated with reverse left ventricular remodeling and improved left ventricular systolic function. However, the underlying mechanisms that contribute to these symptomatic and prognostic benefits are largely unknown. The aim of this study is to evaluate left ventricular hemodynamics in patients treated with Sacubitril-Valsartan using non-invasive pressure-volume analysis.

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Sacubitril-Valsartan

Observational study during the clinically indicated treatment

Sponsors & Collaborators

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Daniel Lavall, MD · University of Leipzig

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-21
Primary Completion
2025-12-31
Completion
2026-04-08
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04498780 on ClinicalTrials.gov